Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Novartis pipeline in Phase 3
Solid Tumors
Hematology
Appendix
Innovation: Clinical trials
References
Abbreviations
8 lead indications
Lead indication
Code
AAA617
Name
Mechanism
Indication(s)
Code
Name
PluvictoⓇ
Radioligand therapy target PSMA mCRPC, pre-taxane
ABL001
Scemblix
AAA6011) Lutathera®
ACZ885
canakinumab
IL-1b inhibitor
Metastatic hormone sensitive prostate cancer (mHSPC)
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
NSCLC, adjuvant
CTL019
ETB115
KymriahⓇ
Promacta®
LNP023
iptacopan
CFB inhibitor
BYL719
Piqray®
PI3Ka inhibitor
HER2+ adv BC
Triple negative breast cancer Ovarian cancer
DRB436
Tafinlar +Mekinist®
BRAF inhibitor + MEK inhibitor
Thyroid cancer
MBG453
YTB323
sabatolimab
YTB323
TIM3 antagonist
CD19 CAR-T
Mechanism
BCR-ABL inhibitor
CD19 CAR-T
Thrombopoietin receptor
(TPO-R) agonist
Indication(s)
Chronic myeloid leukemia, 1st line
1L high risk acute lymphocytic leukaemia, pediatrics & young adults
Radiation sickness syndrome
Paroxysmal nocturnal haemoglobinuria
Atypical haemolytic uraemic syndrome
Myelodysplastic syndrome
2L Diffuse large B-cell lymphoma³)
INC280
Tabrecta®
Met inhibitor
Non-small cell lung cancer
JDQ443 JDQ443
KRAS inhibitor
2/3L Non-small cell lung cancer
LEE011 Kisqali®
CDK4 Inhibitor
NIS793
NIS793
TGFB1 inhibitor
VDT482
Tislelizumab
PD1 inhibitor
HR+/HER2- BC (adj)
1L Nasopharyngeal Carcinoma
1L ESCC
1L Metastatic pancreatic ductal adenocarcinoma
Adj/Neo adj. NSCLC
1L Hepatocellular Carcinoma
1L Gastric cancer
Localized ESCC
Code Name
KJX839 Leqvio®
LCZ696 EntrestoⓇ
LNP023 iptacopan
Cardiovascular, Renal, Metabolism
Mechanism
siRNA (regulation of LDL-C)
Angiotensin receptor/neprilysin
inhibitor
CFB inhibitor
Indication(s)
CVRR-LDLC
Hyperlipidemia, pediatrics
Congestive heart failure, pediatrics²)
IgA nephropathy
1L Urothelial Cell Carcinoma
1L Small Cell Lung Cancer
TQJ230 Pelacarsen
ASO targeting Lp(a)
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Immunology
Code
Name
Mechanism
AIN457
Cosentyx®
IL17A inhibitor
LOU064 remibrutinib
VAY736 ianalumab
Others
Indication(s)
Lupus Nephritis
Axial SpA (IV formulation)
Giant cell arteritis
Hidradenitis suppurativa
Code
Name
Mechanism
Indication(s)
Psoriatic arthritis (IV formulation)
Global Health
COA566 Coartem®
Malaria, uncomplicated (<5kg patients)
BTK inhibitor
Chronic spontaneous urticaria
Respiratory & Allergy
IGE025 XolairⓇ
BAFF-R inhibitor
Lupus Nephritis³)
IgE inhibitor
Food allergy
Auto-injector
IgE inhibitor
Neuroscience
Code
Name
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
QGE031 ligelizumab
Ophthalmology
RTH258 Beovu®
VEGF inhibitor
Food allergy
Diabetic retinopathy
Biosimilars
Code
GP2411
Name
denosumab
SOK583 aflibercept
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
1. 177 Lu-dotatate in US. 2. Approved in US. 3. Ph3 to be initiated in 2022.
40 Investor Relations | Q1 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation